Front > HEALTHCARE

HEALTHCARE

Protalix  / Photo: Paul Orlive Protalix up 74% after positive Fabry disease trial results

The 12-month interim data from the first 16 of 22 adult patients enrolled demonstrate a mean improvement in kidney function.

Kare Schultz Photo: PR Teva jumps as US global opioid settlement moves nearer

"Reuters" reports that a federal judge has summoned Teva CEO Kare Schultz to discuss settling all 2,600 US suits alleging that the Israeli company fueled the opioid crisis.

Together-Cannabliss Together begins growing cannabis commercially in Israel

The company has reported that it has switched to commercial cultivation at its farm in Ashkelon, after receiving IMC-GAP approval for the facility.

Teva Photo: ASAP Creative Shutterstock Teva among cos offering $50b settlement of opioid claims

According to a report by Reuters, five pharmaceuticals and distribution companies involved in the opioids affair in the US are offering drugs worth $22 billion and services worth $28 billion.

Teva IBI: $15b in free drugs would only cost Teva $2b-4b

IBI Investment House pharma analyst Steven Tepper has calculated that the cost to Teva of a $15 billion opioid settlement would be dramatically less.

Mori Arkin  / Photo: PR Exalenz Bioscience seeks buyer

The company's trial of one product failed, and it downwardly revised its sales guidance.

Teva Photo: Sivan Faraj Teva offers $15b in drugs to settle opioid cases - report

The settlement would run over 10 years and the drugs would include Teva's Narcan for treating opioid addiction, sources told "Bloomberg."

Dov Tamarkin  / Photo: Ofir Farajun Cannabis co Intelicanna appoints Dov Tamarkin to board

Dr. Tamarkin founded Foamix Pharmaceuticals, which develops and commercializes pharmaceuticals in the dermatology sector.

Eyesight Photo: Shutterstock Orasis Pharmaceuticals reports presbyopia treatment trial success

The company says that its CSF-1 eye drops demonstrated significant improvement in near visual acuity in a Phase 2b trial.

Dr. Michael Hayden Photo: Tamar Matsafi Teva spin-off 89bio files for $70m Wall Street IPO

The Israeli biopharmaceutical company's lead candidate treats NASH, a severe form of nonalcoholic fatty liver disease.

Pnina Fishman photo: Eyal Izhar Capital Point's hostile bid for Can-Fite ends in compromise

Dr. Pnina Fishman will continue as Can-Fite BioPharma's CEO.

Medicine Photo: Reuters Israel's RDD Pharma merges with Innovate Biopharmaceuticals

The merged company will be listed on Nasdaq under the name 9 Meters Biopharma.

Teva logistics center Photo: PR Amot buys Teva's logistics center for NIS 445m

Amot will lease back the logistics center to Teva subsidiary SLE, in a deal that will help improve Teva's current cash flow.

Jeremy Levin "From Teva's ashes new Israeli biotech can grow"

Former Teva CEO Jeremy Levin talks to "Globes" about Israel's biotech potential, the opioid disaster and why he shuns investing in medical cannabis.

Teva Photo: Reuters Ammar Awad Justice Ministry gives nod to Teva bribery settlement

The court still has to approve the settlement with a shareholder who sought to bring a derivative action.

Dr. Irit Yaniv and Amir Blatt Accelmed launches $100m Israeli health-tech fund

The fund will invest in Israeli and global pre-revenue health-tech startups, including medical devices and digital health.

Lihi Segal Photo: PR Longliv invests $5m in microbiome co DayTwo

The Israeli company has developed a microbiome human discovery platform that offers a glycemic control solution for people with type II diabetes.

Len Blavatnik Clal Biotech's immuno-oncology co Elicio raises $33m

The new funds will be used to advance Elicio’s pipeline of novel lymph node targeted immuno-therapies.

Yoel Zabar AngioDynamics to buy Israeli co Eximo Medical

Based in Rehovot, the medical device company has developed a proprietary 355nm wavelength laser technology platform.

Cancerous cells Photo: Shutterstock aMoon invests in $80m Adicet Bio financing round

Based on technology developed by the Technion's Prof. Yoram Reiter, Adicet Bio is developing allogeneic cell therapies for cancer using innovative gamma delta T cells.

meat Ophectra to merge with meat cloning co MeaTech

MeaTech is developing 3D stem cell printing technology for the clean meat sector.

Eric Drape Teva EVP global operations steps down

Dr. Carlo de Notaristefani is being replaced by Eric Drapé.

Arie Belldegrun Photo: PR Prof. Arie Belldegrun sees $1b market for UroGen drugs

The UroGen chairman is sanguine about the prospects for the Israeli drug developer's bladder and urinary tract cancer treatments.

cancer Lung cancer treatment co Body Vision raises $20m

The Israeli company's LungVision 2.0 platform has AI Tomography, fused imaging, cloud-based machine learning and multi-modality image registration.

Rami Epstein  / Photo: PR Stem cell co Kadimastem reports positive ALS results

The company's drug successfully slowed development of Lou Gehrig's disease (ALS) in the treated patients.

Lab Technician.  Photo: Reuters Israel falls into line on generic drug co tax breaks

The move will enhance Israel's attractiveness for investment by international pharmaceutical companies.

Boaz Noy and Tzafra Cohen / Photo: Cadya Levi The super yeasts producing protein and fuel

Israeli company NextFerm has unique technology for turning natural yeasts into industrial power players.

Yaron Gisin and Amit Sade Growing concerns

After Ori Yehudai's about face at cannabis company Sade, Amit Sade talks about what happened, and what makes his company different.

No shade in Dizengoff square Planners to start putting Israel into the shade

Shady places are about as rare as parking places in Israel's cities, but municipalities are finally addressing the matter.

Prof. Gregor Reid Good bacteria, bad products

Microbiome pioneer Prof. Gregor Reid sees vast potential in probiotics for our helath but dismisses 90% of the products sold on the market as useless.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018